20/20 Biolabs (AIDX)
Blood testing for cancer screening and inflammation tracking, plus laboratory services for diagnostic developers.
Something off on this page? Send us feedback.
Offers laboratory-developed blood tests that combine protein biomarkers with proprietary algorithms for cancer screening and inflammation tracking, alongside shared laboratory services and a suspicious-powder screening kit. Most revenue comes from OneTest, whose testing is performed in one Maryland laboratory.
Runs OneTest for Cancer as Standard and Premium laboratory-developed blood tests, combining protein tumor biomarkers with proprietary algorithms to report a likelihood score and guide follow-up imaging, molecular, or tissue testing. Analysis occurs in a CAP-accredited, CLIA-licensed high-complexity laboratory in Gaithersburg, Maryland, using venous or upper-arm capillary samples.
Extends the platform through OneTest for Longevity, which measures inflammation and connects it to diet and lifestyle guidance, and CLIAx, a shared laboratory service for overseas diagnostic developers entering the United States. BioCheck remains a first-responder kit that screens suspicious powders for protein.
Generates most revenue from OneTest through individual, commercial, and professional-health customers. Operations rely on a single Maryland laboratory, external collection partners, licensed BioInfra technology, and the regulatory pathway for laboratory-developed tests.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.5M · Total debt $572.4K · Total assets $6.1M · Shareholders' equity $3.2M
- Revenue
- $730.6K
- Operating income
- −$1.2M
- Net income
- −$1.5M
No dividends on record.
| Institutions | 4.23% | 540.6K shares | |
|---|---|---|---|
| 15 holders · as of Jun 30, 2026 | |||
| Insiders | 14.77% | 1.89M shares | |
| 5 holders · as of Mar 10, 2026 | |||
| Strategic holders | 5.10% | 651.5K shares | |
| 1 holder · as of Mar 10, 2026 | |||
| Other | 75.90% | 9.69M shares | |
| remainder | |||
12.77M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Jonathan M. Cohen1Insiderdirector, 10 percent owner, officer: Chief Executive Officer | 14.36% | 1.83M | filed Mar 10, 2026 |
Full Succeed International LimitedStrategic | 5.10% | 651,465 | filed Mar 10, 2026 |
Cresset Asset Management, LLCInstitution | 1.88% | 240,122 | as of Jun 30, 2026 |
HRT Financial LPInstitution | 0.70% | 89,273 | as of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.41% | 52,087 | as of Jun 30, 2026 |
- Jonathan M. Cohen's transaction reports restate only vehicles that traded; the 2026 ownership statement (1.83M) is used instead.
Insider tradesForm 4
No open-market trades in the last 12 months.
- GRAIL
Commercial multi-cancer blood screening with much greater clinical scale.
- Abbott
National multi-cancer blood screening through Cancerguard.
- Guardant Health
Blood-based cancer screening for the same asymptomatic adults.
- Freenome
AI-enabled blood screening and a competing multiomics platform.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| 20/20 Biolabs | $0.4682 | −0.36% | $5.8M | — | — | 2.8 | — |
| GRAIL | $107.72 | −0.23% | $4.63B | — | — | 28.0 | +25.7% |
| Abbott | $104.23 | +1.21% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| Guardant Health | $176.89 | +1.74% | $23.33B | — | — | 19.7 | +44.3% |
| Freenome | $16.61 | +0.06% | $135.4M | — | — | — | — |
| Median | 33.1 | 18.0 | 19.7 | +25.7% |